Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide with RT and LHRH Agonist in Prostate Cancer
NCT02023463Phase 1Active, not recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Apr 2014
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Thomas Jefferson University. Primary endpoint: Acute toxicities. Started Apr 2014; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02023463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02023463.